Cellectis draws down second tranche under EIB credit facility

gorodenkoff Cellectis ( NASDAQ: CLLS ) said it has drawn down a second tranche of EUR 15M under a credit facility agreement with the European Investment Bank, or EIB. The biotech said the agreement is for up to EUR 40M and was entered into in December 2022. The second tranche is expected to be disbursed by Jan.

25. As a condition of the disbursement, Cellectis issued 1.46M warrants to the benefit of the EIB, the company said in a statement . Each warrant allows the EIB to subscribe for one ordinary share at an exercise price of EUR 2.53. The EIB agreement allows the company to draw down a third tranche of up to EUR 5M, subject to certain conditions.

Cellectis plans to use proceeds from the second tranche for development of its allogeneic Car T cell product candidates UCART22, UCART20x22 and UCART 123. More on Cellectis Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript Cellectis: End Of 2023 Data Readouts To Boost CAR T Prospects Biggest stock movers today: Target, ZIM Integrated Shipping, JD.com, and more Cellectis stock jumps on execution of $140M additional investment by AstraZeneca Seeking Alpha’s Quant Rating on Cellectis.